Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Serious Games

Date Submitted: Oct 24, 2023
Date Accepted: Aug 16, 2024

The final, peer-reviewed published version of this preprint can be found here:

Effects of Virtual Reality Therapy for Patients With Breast Cancer During Chemotherapy: Randomized Controlled Trial

Li m, Yu z, Li h, Cao l, Yu h, Deng n, Liu y

Effects of Virtual Reality Therapy for Patients With Breast Cancer During Chemotherapy: Randomized Controlled Trial

JMIR Serious Games 2024;12:e53825

DOI: 10.2196/53825

PMID: 39417797

PMCID: 11500621

Effects of virtual reality therapy for breast cancer patients during chemotherapy: A randomized controlled trial

  • mengdan Li; 
  • zhifu Yu; 
  • hui Li; 
  • li Cao; 
  • huihui Yu; 
  • ning Deng; 
  • yunyong Liu

ABSTRACT

Background:

Breast cancer patients suffer high levels of psychological and physical pain. Virtual reality (VR) may be an acceptable, safe intervention to alleviate the negative emotions and pain of cancer patients.

Objective:

We aimed to test the long-term effects of VR on psychological distress, quality of life (QOL), and medication adherence compared with traditional care in Chinese breast cancer patients. We also explored the intervention mechanism and the acceptability of VR.

Methods:

A total of 327 eligible participants were randomly assigned to a VR intervention group or a control group. The Distress Thermometer (DT), Quality of Life Questionnaire version 3.0 (QLQ-C30), 8-item Morisky Medication Adherence Scale (MMAS-8), and Virtual Reality Symptom Questionnaire (VRSQ) were assessed at baseline, post-intervention (three months), and follow-up (six months). Analysis followed the intention-to-treat principle. The generalized estimating equations (GEE) model was used to analyze the longitudinal data, and the PROCESS macro was used to analyze the mediating effect.

Results:

Compared with the control group, distress scores decreased significantly (P = .02), and QOL (emotional functioning, cognitive functioning, social functioning) and medication adherence scores improved after three months of VR interventions (P < .05). These effects persisted at follow-up (all P < .05), except for medication adherence (P = .12). Psychological distress had mediating effects on the longitudinal association between VR interventions and the global health status and the five functional subscales (indirect effect = 4.572−6.672, all P < .05).

Conclusions:

This research demonstrated that VR intervention technology may help reduce distress and improve health-related quality of life in all dimensions for breast cancer patients over time. By incorporating a mediating analysis, we showed that the QOL benefits of VR interventions were manifested through positive effects on psychological distress risk factors. Clinical Trial: The study was registered in the Chinese Clinical Trial Registry (Number: ChiCTR2000035049; Date: 2020.7.29).


 Citation

Please cite as:

Li m, Yu z, Li h, Cao l, Yu h, Deng n, Liu y

Effects of Virtual Reality Therapy for Patients With Breast Cancer During Chemotherapy: Randomized Controlled Trial

JMIR Serious Games 2024;12:e53825

DOI: 10.2196/53825

PMID: 39417797

PMCID: 11500621

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.